we are determined to keep an eye on FDA announcements concerning Docetaxel
San Diego, CA (PRWEB) June 24, 2014
AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Docetaxel.
The FDA issued a safety communication on June 20, warning that Docetaxel may cause patients to experience intoxication or feel drunk. Docetaxel is a chemotherapy drug used to treat different kinds of cancer, including non-small-cell lung cancer, head and neck cancers, stomach, prostate, and cancers of the breast.
FDA’s reason for the warning is that Docetaxel contains ethanol which may cause intoxication or patients feel drunk during and after treatment. To warn about his risk, the Agency is revising the labels of all docetaxel products.
Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Docetaxel and inform the public. For that reason," he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”
The FDA advises “Health care professionals should consider the alcohol content of docetaxel when prescribing or administering the drug to patients, particularly in those whom alcohol intake should be avoided or minimized and when using it in conjunction with other medications.”
AttorneyOne.com has further information on Docetaxel at the website including latest major drug and medical products law news.
Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/06/prweb11961506.htm